The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases

Deng-hua Pan1
Dong-yue Wen1
Yi-huan Luo2
Gang Chen3
Hong Yang1
Jun-qiang Chen2
Yun He1

1Department of Ultrasonography, 2Department of Gastrointestinal Surgery, 3Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China

Background: Growing evidence has demonstrated that Ki-67/MIB-1 has an effect on the clinical progression and prognosis in cancers. However, the diagnostic and prognostic values of Ki-67/MIB-1 in thyroid cancer remain unclear.

Materials and methods: The meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were retrieved from PubMed, EBSCO, EMBASE, ISI Web of Science, China National Knowledge Infrastructure, WanFang and Chinese VIP databases. MetaDiSc and STATA12.0 were used to analyze the meta-analysis. Fixed-effect analysis and random-effect analysis were applied to pool the relative ratio based on heterogeneity in this meta-analysis.

Results: In the meta-analysis, 51 eligible studies were included. The pooled sensitivity of Ki-67/MIB-1 was 0.61 (95% confidence interval [CI]: 0.59–0.63) and specificity was 0.75 (95% CI: 0.74–0.77) in thyroid cancer. The pooled positive likelihood ratio was 3.19 (95% CI: 2.30–4.42) and negative likelihood ratio was 0.43 (95% CI: 0.35–0.54). In the diagnosis of thyroid cancer, the pooled diagnostic odds ratio of Ki-67/MIB-1 was 8.54 (95% CI: 5.03–14.49). The area under the symmetric receiver operating characteristic curve was 0.804 (standard error =0.031). Our results showed that there were statistical associations between Ki-67/MIB-1 and age (odds ratio [OR]=1.71, 95% CI: 1.14–2.57, P=0.010), tumor size (OR=1.86, 95% CI: 1.17–2.96, P=0.008), lymph node metastasis (OR=2.49, 95% CI: 1.42–4.39, P=0.002), metastasis status (OR=6.96, 95% CI: 2.46–19.69, P<0.001), tumor node metastasis stage (OR=6.56, 95% CI: 3.80–11.34, P<0.001) and extrathyroid extension (OR=1.91, 95% CI: 1.27–2.87, P=0.002). Furthermore, thyroid cancer patients with a high level of Ki-67/MIB-1 had a worse disease-free survival as compared to patients with a low level of Ki-67/MIB-1 (hazard ratio =5.19, 95% CI: 3.18–8.46, P<0.001). Also, Ki-67/MIB-1 was found to be associated with increased risk of mortality (hazard ratio =3.56, 95% CI: 1.17–10.83, P=0.025).

Conclusion: Our results demonstrated that Ki-67/MIB-1 might act as a potential factor in diagnosing thyroid cancer in Chinese. Also, the meta-analysis indicated that Ki-67/MIB-1 might have an effect on prognosis in non-Chinese thyroid cancer patients.

Keywords: thyroid cancer, Ki-67/MIB-1, diagnosis, progression, prognosis, meta-analysis

Introduction
Thyroid carcinoma, accounting for nearly 1% of all the cancers, is the most common malignancy in the endocrine organs.1 Traditionally, thyroid carcinomas are classified into papillary thyroid cancer (PTC), follicular thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid cancer and anaplastic thyroid cancer, based on histopathology.2 In China, it has been reported that 90 per 100,000 people were...
diagnosed with thyroid cancer and 6.8 people died among these patients. In USA, it has been estimated that 1,980 people died of the disease in 2016 and there will be 64,300 new patients of thyroid cancer. The diagnosis of thyroid cancer is often based on magnetic resonance imaging, ultrasound, computed tomography, fine needle aspiration and radionuclide imaging. Although various methods are well applied in clinics, patients often have poor outcome. Reports have shown that the patients’ age when being diagnosed, sex, tumor size, lymph node, distant metastases and pathologic differentiation of the cancer are the risk factors of prognosis in thyroid cancer.\(^5\)\(^-\)\(^^8\)

However, no studies showed the markers had prognostic value in thyroid cancer. Cell proliferative activity is an important factor in cancer biologic behavior. Ki-67, considered as a nuclear antigen, is expressed in all cell nuclei, except those in the G0 phase. Further, MIB-1 acts as a monoclonal antibody which increases against Ki-67. In recent years, Ki-67 has been studied in many cancers, including cervical cancer, lung cancer, breast cancer\(^9\) and thyroid cancer.\(^10\) It has been reported that Ki-67 is an independent prognostic factor in thyroid cancer patients.\(^11\) A study predicted that patients with Ki-67 labeling index (LI) >3% would show a worse cause-specific survival than those with Ki-67 LI <3%.\(^12\) However, Gnemmi et al\(^13\) reported that Ki-67 LI (≥4%) is an independent factor and predictor of cause-specific survival.

Though many studies have demonstrated Ki-67/MIB-1 is expressed in thyroid cancer, there is no systematic literature assessing the relationship between Ki-67/MIB-1 expression and clinical factors in thyroid cancer patients. So, the significance of Ki-67/MIB-1 for prognostication of thyroid cancer remains uncertain. Thus, a literature-based meta-analysis study was performed to evaluate the diagnostic and prognostic values of Ki-67/MIB-1 in thyroid cancer.

**Materials and methods**

**Studies selection**

Studies were selected to demonstrate the diagnostic and prognostic values of Ki-67/MIB-1 for thyroid cancer. Electronic literatures were searched in PubMed, EBSCO, EMBASE, ISI Web of Science, WanFang, China National Knowledge Infrastructure and Chinese VIP databases from April 1, 1989 to July 31, 2016. The following keywords were used to identify the related publications: “thyroid cancer”, “Ki-67”, “MIB-1”, “proliferative marker”, “proliferative index”, “diagnosis”, “prognostic”, “survival”. The eligible studies were selected in accordance with the following criteria: 1) studies should be published in full assays; 2) the goal of the publication was to illustrate the clinical significance of Ki-67/MIB-1 in primary thyroid cancer; 3) sufficient data were used to determine the connection between Ki-67/MIB-1 and clinicopathologic parameters; 4) when the same patient cohort was reported in different publications, only the most complete and recent study was selected in the meta-analysis.

Also, we screened the references from the reviews and identified articles.

**Data extraction and assessment of study quality**

Three authors (Deng-hua Pan, Dong-yue Wen and Yi-huan Luo) read the studies carefully and independently. The information of the publications was collected from each study: first author’s name, publication date, the number of patients, patient age, country, follow-up time, antibody of testing Ki-67/MIB-1, the method of detecting Ki-67/MIB-1 expression and threshold used for assessing Ki-67/MIB-1 expression positively. True positive, true negative, false positive and false negative were extracted to construct a diagnostic contingency table. Disease-free survival (DFS) or mortality or distant recurrences-free survival was used to measure the effect of Ki-67/MIB-1 expression on survival in thyroid cancer patients. The following clinical parameters were extracted to evaluate the connection between Ki-67/MIB-1 and thyroid cancer aggressiveness: age, tumor size, lymph node metastasis, metastasis status, extrathyroid extension, tumor node metastasis stage. Minimal size of patients and minimal follow-up time are not defined in this meta-analysis. Studies that met the following criteria were excluded: 1) reviews, conference papers, case reports, expertise public opinion, letters, zoopery were not included; 2) studies without sufficient information to calculate the impact of diagnosis, survival and prognosis of Ki-67/MIB-1 in primary thyroid cancer were excluded; 3) studies with duplicated data from similar or the same population were excluded. QUADAS-2 was used to assess the quality of the studies for diagnosis.\(^15\) Newcastle–Ottawa scale (NOS) was used to assess the quality of the studies for prognosis.\(^16\) The study with NOS scores ≥6 was identified as a high-quality study and the study with NOS scores <6 was considered as a low-quality study.

**Statistical methods**

According to the cut-off values, Ki-67/MIB-1 expression was divided into positive and negative groups. The pooled
sensitivity and specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), diagnostic odds ratio (DOR) and the area under the symmetric receiver operating characteristic curve were used to measure the diagnosis of Ki-67/MIB-1 in thyroid cancer. The odds ratio (OR) and 95% confidence intervals (CIs) were used to estimate the relationship between Ki-67/MIB-1 and clinicopathologic parameters in thyroid cancer patients. When the OR was >1, it indicated that high Ki-67/MIB-1 was a risk factor in thyroid cancer. Hazard ratio (HR) and 95% CI were calculated to measure the effect of Ki-67/MIB-1 on prognosis. Also, when the HR was >1, it indicated that high level of Ki-67/MIB-1 was related to worse survival in thyroid cancer patients.

Further, Cochran’s Q-test was performed to measure heterogeneity. Also, I² was calculated to assess the inconsistency of the studies. When I² was over 50% or chi-squared P-value was >0.1, fixed-effect meta-analysis was performed; otherwise, random-effect meta-analysis was used when there was less or no heterogeneity (when I² was less than 50% or chi-squared P-value was <0.1). MetaDiSc was used to measure the diagnosis of Ki-67/MIB-1 in thyroid cancer. STATA12.0 was used to calculate the progression and prognosis of Ki-67/MIB-1 in thyroid cancer. The potential publication bias was investigated through funnel plot and by computation of Begg’s test. When the P-value was <0.05, it was considered significant.

Results
Description of studies
The flow chart of search process is presented in Figure 1. One thousand one hundred and sixty-two relevant studies were identified. After reviewing the abstracts and full text, only 51 studies were found to be eligible and were included in the meta-analysis. The characteristics of these articles are summarized in Tables 1–3. Table 1 gives the main information of the studies included in diagnosis. Thirty-seven studies
| First author | Country | Patients | Type of cancer | Type of control | Antibody | Test method | Threshold, % | TP | FP | FN | TN |
|--------------|---------|----------|----------------|----------------|----------|-------------|-------------|-----|-----|-----|-----|
| Horii et al. | Japan   | 50       | PTC, FTC, ATC  | Adenomatous goiter, FA | Ki-67 monoclonal antibody | IHC | 20          | 276 | 2   | 6   | 15  |
| Huang et al. | China   | 160      | PTC            | FA, goiter       | Mouse monoclonal antibody | IHC | 5           | 103 | 9   | 0   | 128 |
| Chou et al.  | Taiwan  | 46       | PTC, FVPTC     | NG, normal tissue | Mouse monoclonal antibody anti-Ki-67 | IHC | 10          | 16  | 2   | 13  | 15  |
| Nie et al.   | China   | 26       | PTC            | TA, NG, toxic goiter | Anti-Ki-67 | IHC | 25          | 9   | 2   | 5   | 10  |
| Liang et al. | China   | 200      | PTC            | NG, TA          | Ki-67 | IHC | 25          | 93  | 1   | 7   | 99  |
| Gan et al.   | China   | 135      | PTC            | Adjacent tissue of thyroid carcinoma, normal tissue, NG, FA | Mouse monoclonal antibody | IHC | 10          | 38  | 26  | 7   | 64  |
| Wang et al.  | China   | 94       | PTC, FTC, MTC, ATC | NG, TA       | Ki-67 | IHC | 10          | 20  | 0   | 45  | 29  |
| Shang et al. | China   | 100      | PTC, FTC, OCTC | PTA, FTA, OCTA  | Anti-Ki-67 | IHC | 1.50        | 42  | 29  | 8   | 21  |
| Cui et al.   | China   | 87       | PTC, FTC       | TA, normal tissue | Mouse monoclonal antibody | IHC | 10          | 35  | 3   | 19  | 20  |
| Feng et al.  | China   | 199      | PTC, FTC, MTC  | NG, FA, adjacent tissue of thyroid carcinoma | Ki-67 | IHC | 5           | 58  | 16  | 18  | 107 |
| Jin et al.   | China   | 79       | PTC, FTC, MTC, ATC | TA, normal thyroid gland tissue beside adenoma | Mouse monoclonal antibody | IHC | 25          | 39  | 3   | 17  | 20  |
| Huang et al. | China   | 70       | PTC            | Thyroid hyperplasia, TA | Anti-Ki-67 | IHC | 10          | 20  | 9   | 10  | 31  |
| Li and Du    | China   | 136      | PTC            | NG, NG with adenoma hyperplasia, NGWPH | Anti-Ki-67 | IHC | 10          | 55  | 27  | 0   | 54  |
| Hao et al.   | China   | 236      | PTC            | NG, TA          | Ki-67 | IHC | ND          | 17  | 2   | 101 | 116 |
| Song et al.  | China   | 592      | PTC            | NG, nonmalignant follicular adenoma | Mouse monoclonal antibody | IHC | 10          | 179 | 56  | 262 | 95  |
| Tan et al.   | Turkey  | 39       | PTC, FTC       | FA              | Ki-67 | IHC | 5           | 8   | 10  | 6   | 5   |
| Zeng et al.  | China   | 108      | TC              | Normal tissue   | Mouse monoclonal antibody | IHC | 5           | 46  | 11  | 22  | 29  |
| Qin et al.   | China   | 120      | PTC            | NG, normal tissue | Anti-Ki-67 | IHC | 10          | 25  | 78  | 15  | 1   |
| Zhao et al.  | China   | 129      | PTC            | Multinodular goiter, follicular adenomas, Hashimoto's thyroiditis | Ki-67 | IHC | ND          | 34  | 22  | 9   | 64  |
| Jiang et al. | China   | 63       | PTC            | TA              | Mouse monoclonal antibody | IHC | 10          | 23  | 2   | 12  | 26  |
| Yao et al.   | China   | 103      | PTC, FTC, MTC, ATC | Normal tissue, NG, FA | Mouse monoclonal antibody | IHC | 25          | 60  | 10  | 8   | 25  |
| Yang et al.  | China   | 55       | FTC            | FA              | Mouse monoclonal antibody | IHC | 5           | 15  | 6   | 17  | 17  |
| Li et al.    | China   | 246      | PTC            | Normal tissue, NG, NGWPH | Mouse monoclonal antibody | IHC | 10          | 68  | 22  | 8   | 68  |
| Shi et al.   | China   | 130      | TC              | TA, NG, normal thyroid gland tissue | Rabbit monoclonal antibody | IHC | 10          | 42  | 10  | 8   | 70  |
| Zhang et al. | China   | 146      | PTC            | Multinodular goiter | Ki-67 | IHC | 1.65        | 57  | 9   | 19  | 61  |
| Maruta et al.| Japan   | 108      | FC              | FA              | Anti-Ki-67 | IHC | 50          | 47  | 35  | 21  | 5   |
| Guo et al.   | China   | 117      | PTC, FTC, ATC  | TA, normal thyroid tissues | Anti-Ki-67 | IHC | 10          | 62  | 2   | 87  | 30  |
| Wang et al.  | China   | 33       | PTC            | Hylalinizing trabecular tumor | MB-1 | IHC | 10          | 20  | 10  | 0   | 3   |
| Zhou et al.  | China   | 120      | PTMC           | TA, NG, Hashimoto's thyroiditis | Anti-Ki-67 | IHC | 25          | 34  | 6   | 46  | 34  |
| Li et al.    | China   | 370      | PTC            | Benign thyroid nodule | Mouse monoclonal antibody | IHC | 1.00        | 112 | 48  | 68  | 142 |
| Xu et al.    | China   | 62       | PTC            | Thyroid benign tumor | Ki-67 | IHC | 5           | 32  | 3   | 14  | 13  |
| Wang et al.  | China   | 95       | PTC            | NGWPH           | Ki-67 | IHC | 10          | 26  | 44  | 19  | 6   |
| Zhou et al.  | China   | 158      | PTMC           | NG, TA, Hashimoto’s thyroiditis | Mouse monoclonal antibody | IHC | 25.00       | 50  | 7   | 58  | 43  |
| Zhu et al.   | China   | 96       | PTC            | Thyroid hyperplasia | Anti-Ki-67 | IHC | 5           | 40  | 10  | 24  | 22  |
| Li and Pu    | China   | 150      | PTC            | Follicular adenoma, normal tissue | Ki-67 | IHC | 5           | 18  | 9   | 32  | 91  |
| Li and Zhang | China   | 120      | PTC            | TA, NG, normal tissue | Mouse monoclonal antibody | IHC | 10          | 25  | 8   | 5   | 82  |
| Feng and Wang| China   | 60       | MTC            | Multinodular goiter, follicular adenomas, Hashimoto's thyroiditis | Mouse monoclonal antibody | IHC | 1           | 36  | 0   | 6   | 18  |

**Abbreviations:** ATC, anaplastic thyroid cancer; FA, follicular adenoma; FN, false negative; FP, false positive; FTA, follicular thyroid adenoma; FTC, follicular carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; iHC, immunohistochemistry; MTC, medullary thyroid carcinoma; ND, no data; NG, nodular goiter; NGWPH, nodular goiter with papillary hyperplasia; PTA, papillary thyroid adenoma; OCTA, oxyphilic cell thyroid adenoma; OCTC, oxyphilic cell thyroid carcinoma; PTC, papillary thyroid carcinoma; PTMC, papillary thyroid microcarcinoma; TA, thyroid adenoma; TP, true positive; TN, true negative.
### Table 2: The relationships between Ki-67/MiB-1 expression and clinicopathologic parameters

| Clinicopathologic parameters | Studies (n) | Test group | Control group | Heterogeneity | Meta-analysis model | OR (95% CI) | P-value |
|-----------------------------|-------------|------------|---------------|---------------|---------------------|-------------|---------|
| Age (45 years)              | 10          | 124        | 303           | 91            | 239                 | 0.00        | 0.806   |
| Tumor size (4 cm)           | 5           | 35         | 165           | 76            | 730                 | 2.00        | 0.395   |
| Lymph node metastasis       | 15          | 233        | 345           | 226           | 509                 | 50.20       | 0.014   |
| Metastasis status           | 7           | 75         | 133           | 121           | 920                 | 59.80       | 0.021   |
| TNM stage                   | 7           | 113        | 146           | 103           | 247                 | 0.00        | 0.96    |
| Extrathyroid extension      | 4           | 64         | 225           | 79            | 413                 | 31.30       | 0.224   |

**Abbreviations:** CI, confidence interval; OR, odds ratio; TNM, tumor node metastasis.

### Table 3: The features of the studies relating Ki-67/MiB-1 to patients’ prognosis

| Type of survival | First author | Country | Year | Patients | Age | Median FU | Test method | Antibody | Threshold, % | HR (95% CI) | P-value |
|------------------|-------------|---------|------|----------|-----|-----------|-------------|-----------|--------------|-------------|---------|
| DFS              | Kjellman et al | Sweden | 2003 | 30       | 62  | 146 months | IHC         | MIB-1     | 1.85         | 4.93 (1.91–12.77) | 0.001   |
|                  | Ito et al   | Japan   | 2010 | 371      | 49  | 125 months | IHC         | Anti Ki-67 antibody | 1          | 4.13 (2.19–7.75) | <0.001   |
|                  | Miyauchi et al | Japan | 2013 | 390      | 50.8| 88 months  | IHC         | Anti Ki-67 antibody (clone MIB-1) | >10        | 15.33 (4.13–56.96) | <0.001   |
| Mortality        | Wang et al  | Sweden  | 1996 | 21       | 53  | 10.5 years | IHC         | Ki-67     | 5            | 0.514 (0.006–3.089) | 0.467   |
|                  | Tisel et al | Sweden  | 2003 | 36       | 45  | 20 years   | IHC         | Anti-Ki67  | 1            | 2.12 (0.862–5.233) | 0.102   |
|                  | Ito et al   | Japan   | 2010 | 371      | 49  | 125 months | IHC         | Anti Ki-67 antibody | 3          | 25.64 (2.49–250)  | 0.006   |
|                  | Chen et al  | USA     | 2011 | 9        | 64.8| 32.5 months| IHC         | MIB-1     | 5            | 0.088 (0.008–1.026) | 0.052   |
|                  | Miyauchi et al | Japan | 2013 | 390      | 50.8| 88 months  | IHC         | Anti Ki-67 antibody (clone MIB-1) | >10        | 34.08 (3.81–305.16) | 0.002   |
|                  | Gnemmi et al | France | 2014 | 82       | ND  | 68 months  | IHC         | MiB-1     | 4            | 6.126 (1.662–22.574) | 0.007   |
|                  | Jovanovic et al | Macedonia | 2015 | 20      | 51.2| 73 months  | IHC         | MIB-1     | 6.50         | 24.25 (3.63–161.99) | 0.001   |
|                  | Feng et al  | China   | 2014 | 42       | 53.2| 7.8 years  | IHC         | MIB-1     | 1            | 2.28 (0.61–8.55)   | 0.228   |
|                  | Gmenni et al | France | 2014 | 82       | ND  | 68 months  | IHC         | MIB-1     | 4            | 7.322 (3.141–17.07) | <0.001   |

**Abbreviations:** CI, confidence interval; DFS, disease-free survival; DRFS, distant recurrences-free survival; FU, follow-up; HR, hazard ratio; IHC, immunohistochemistry; ND, no data.
detecting the diagnostic value of Ki-67/MIB-1 in thyroid cancer were included in our analysis, including 4,818 samples (2,601 cases and 2,217 controls). The quality assessment of the included studies in diagnosis is shown in Figure 2. The risks of bias in “index test” and “reference standard” were unclear in this meta-analysis. Table 2 shows the correlation between clinicopathologic parameters and Ki-67/MIB-1, including 4,375 samples (1,317 cases and 3,058 controls). As shown in Table 3, a total of 10 studies reporting the relation between Ki-67/MIB-1 and thyroid cancer patient survival were included, of which three studies had data on DFS, seven on mortality and only one on distant recurrences-free survival (DRFS). The studies included in survival analysis had 1,083 samples. The age of patients ranged from 45 to 64.8 years, and the median follow-up time ranged from 68 months to 20 years. Immunohistochemistry (IHC) was used to detect the expression of Ki-67/MIB-1 in all the included studies. The cut-off value ranged from 1% to 10%. The quality assessment of the studies included in prognosis is shown in Table 4.

**Effect of Ki-67/MIB-1 on diagnosis**

Due to heterogeneity, random-effect model was used to calculate the overall performance of Ki-67/MIB-1 in thyroid tissues in diagnosing thyroid cancer. Ki-67/MIB-1 was found to be a valuable diagnostic factor for thyroid cancer. The pooled sensitivity was 0.61 (95% CI: 0.59–0.63; Figure 3A) and specificity was 0.75 (95% CI: 0.74–0.77; Figure 3B). The pooled LR+ was 3.19 (95% CI: 2.30–4.42; Figure 3C) and the pooled LR− was 0.43 (95% CI: 0.35–0.54; Figure 3D). The pooled DOR of Ki-67/MIB-1 was 8.54 (95% CI: 5.03–14.49; Figure 4). The area under the symmetric receiver operating characteristic curve was 0.804 (standard error = 0.031; Figure 5).

For Ki-67/MIB-1, the summary indexes of 37 studies are displayed in forest plots. High heterogeneity was found in sensitivity ($I^2$=94.5%, $P<0.001$) and specificity ($I^2$=94.7%, $P<0.001$). Also, subgroup analysis was performed to identify the possible reasons for heterogeneity. There were 12 studies with Ki-67/MIB-1 cut-off value ≤5%, which revealed a pooled sensitivity of 0.70 (95% CI: 0.67–0.73), specificity of 0.80 (95% CI: 0.77–0.83) and DOR of 7.49 (95% CI: 3.61–15.52). Fifteen studies had Ki-67/MIB-1 cut-off value of 10%, a pooled sensitivity of 0.56 (95% CI: 0.53–0.59), specificity of 0.67 (95% CI: 0.63–0.70) and DOR of 7.73 (95% CI: 2.68–22.30). There were eight studies with a cut-off value >10%, and the pooled sensitivity, specificity and DOR were 0.78 (95% CI: 0.75–0.81), 0.79 (95% CI: 0.74–0.84) and 15.40 (95% CI: 3.41–69.62), respectively. In the subgroup analysis of PTC, the results showed that the pooled sensitivity, specificity and DOR were 0.63 (95% CI: 0.60–0.65), 0.74 (95% CI: 0.72–0.76) and 8.22 (95% CI: 4.08–16.56), respectively. In the subgroup analysis of

---

**Table 4** Quality assessment of included studies according to NOS

| First author | Year | Selection | Comparability | Outcome | Total score |
|--------------|------|-----------|---------------|---------|-------------|
| Kjellman et al | 2003 | * * * | * * | * | 6 |
| Feng and Wang | 2015 | * * * | * * | * | 6 |
| Ito et al | 2010 | * * * | * * | * | 6 |
| Jovanovic et al | 2015 | * * * | * * | * | 6 |
| Gnemmi et al | 2014 | * * * | * * | * | 7 |
| Myauxchi et al | 2013 | * * * | * * | * | 5 |
| Chen et al | 2011 | * * * | * * | * | 6 |
| Wang et al | 1996 | * * * | * * | * | 6 |
| Tisell et al | 2003 | * * * | * * | * | 6 |

**Notes:** A: representative of the exposed cohort; B: selection of the nonexposed cohort; C: ascertainment of exposure; D: demonstration that outcome of interest was not present at the start of study; E: comparability of cohorts on the basis of the design or analysis; F: assessment of outcome; G: adequacy of follow-up for outcomes to occur (≥2 years or outcomes occurred in all patients); H: adequacy of follow-up of cohorts (follow-up rate ≥75%).

**Abbreviation:** NOS, Newcastle–Ottawa scale.
2.48–9.17), respectively (Table S1). For papillary thyroid microcarcinoma (PTMC), the results showed that the pooled sensitivity, specificity, and DOR were 0.45 (95% CI: 0.37–0.52), 0.86 (95% CI: 0.77–0.92) and 4.76 (95% CI: 3.26–7.98), respectively (Table S1).

**Associations of Ki-67/MIB-1 with clinicopathologic parameters**

Table 2 shows the main results of the effects value of Ki-67/ MIB-1 on clinicopathologic parameters in thyroid cancer.

---

**Figure 3** Forest plots for the accuracy of Ki-67/MIB-1 for the diagnosis of thyroid cancer.

- **Notes:** (A) Sensitivity; (B) specificity; (C) positive LR (LR+); (D) negative LR (LR−).

- **Abbreviations:** CI, confidence interval; df, degrees of freedom; LR, likelihood ratio.
patients. The results suggested that older patients (>45 years old) had high level of Ki-67/MIB-1 with a pooled OR of 1.71 (95% CI: 1.14–2.57, \(P=0.010\); \(I^2=0.00\%\), \(P=0.806\); Figure 6A). The level of Ki-67/MIB-1 was higher in large tumor size (>4 cm) than in small-sized tumor (<4 cm; pooled OR =1.86, 95% CI: 1.17–2.96, \(P=0.008\); \(I^2=2.00\%\), \(P=0.395\); Figure 6B). Overall, 15 studies had data to estimate the relationship between Ki-67/MIB-1 and lymph node metastasis. The pooled OR estimated from 15 studies indicated that Ki-67/MIB-1 was lower in negative lymph node metastasis than in positive lymph node metastasis (pooled OR =2.49, 95% CI: 1.42–4.39, \(P=0.002\); \(I^2=50.20\%\), \(P=0.014\); Figure 6C). Also, the association between Ki-67/MIB-1 and metastasis status was calculated and the combined OR was 6.96 (95% CI: 2.46–19.69, \(P<0.001\); Figure 6D). The combined OR for tumor node metastasis stage was 6.56 (95% CI: 3.80–11.33, \(P<0.001\); \(I^2=0.00\%\), \(P=0.960\)). The meta-analysis showed overexpression of Ki-67/MIB-1 for the diagnosis of thyroid cancer was 8.54 (95% CI: 5.03–14.49). The area under the SROC curve was 0.804 (Se =0.72, 95% CI: 0.65–0.86). In subgroup analysis, no significant difference was found among patients with Ki-67/MIB-1 cut-off value >10% (HR =3.81–305.00, \(P=0.002\)) by subgroup analysis. Nevertheless, when Ki-67/MIB-1 was more than 5%, the patients were afflicted with poor mortality (HR =28.06, 95% CI: 6.68–117.87, \(P<0.001\)) in thyroid cancer. No connection was found between Ki-67/MIB-1 and thyroid cancer when Ki-67/MIB-1 was less than 5% (HR =1.98, 95% CI: 0.65–6.06, \(P=0.230\)). In subgroup analysis, no significant association was found between medullary thyroid cancer and mortality (HR =0.96, 95% CI: 0.24–2.16).

Impact of Ki-67/MIB-1 expression on survival in thyroid cancer

Furthermore, three studies assessing the association of Ki-67/MIB-1 expression on DFS were identified in this meta-analysis. The combined HR was 5.19. It was demonstrated that overexpression of Ki-67/MIB-1 was associated with worse DFS in thyroid cancer by fixed-effect model (95% CI: 3.18–8.46, \(P<0.001\); \(I^2=36.1\%\), \(P=0.209\); Figure 7). The meta-analysis showed overexpression of Ki-67/MIB-1 had effect on mortality (HR =3.56, 95% CI: 1.17–10.83, \(P=0.025\)) in eight studies, with heterogeneity (\(I^2=73.5\%\), \(P<0.001\); Figure 8). Worsened mortality was found among patients with Ki-67/MIB-1 cut-off value >10% (HR =34.08, 95% CI: 3.81–305.00, \(P=0.002\)) by subgroup analysis.

Notes: The area under the SROC curve was 0.804 (Se =0.72). \(Q^*\) represents the index to judge the accuracy of the diagnostic experiment.

Abbreviations: AUC, area under the curve; CR, confidence interval; df, degrees of freedom; DOR, diagnostic odds ratio; OR, odds ratio.

Impact of Ki-67/MIB-1 expression on survival in thyroid cancer

Furthermore, three studies assessing the association of Ki-67/MIB-1 expression on DFS were identified in this meta-analysis. The combined HR was 5.19. It was demonstrated that overexpression of Ki-67/MIB-1 was associated with worse DFS in thyroid cancer by fixed-effect model (95% CI: 3.18–8.46, \(P<0.001\); \(I^2=36.1\%\), \(P=0.209\); Figure 7). The meta-analysis showed overexpression of Ki-67/MIB-1 had effect on mortality (HR =3.56, 95% CI: 1.17–10.83, \(P=0.025\)) in eight studies, with heterogeneity (\(I^2=73.5\%\), \(P<0.001\); Figure 8). Worsened mortality was found among patients with Ki-67/MIB-1 cut-off value >10% (HR =34.08, 95% CI: 3.81–305.00, \(P=0.002\)) by subgroup analysis. Nevertheless, when Ki-67/MIB-1 was more than 5%, the patients were afflicted with poor mortality (HR =28.06, 95% CI: 6.68–117.87, \(P<0.001\)) in thyroid cancer. No connection was found between Ki-67/MIB-1 and thyroid cancer when Ki-67/MIB-1 was less than 5% (HR =1.98, 95% CI: 0.65–6.06, \(P=0.230\)). In subgroup analysis, no significant association was found between medullary thyroid cancer and mortality (HR =0.96, 95% CI: 0.24–2.16).
### Figure 6 (Continued)

#### A

| Study ID           | OR (95% CI)       | % weight |
|--------------------|-------------------|----------|
| Tisel et al        | 9.82 (1.04–92.78) | 1.69     |
| Lee et al          | 2.66 (0.12–58.12) | 1.72     |
| Jin et al          | 3.25 (0.80–13.17) | 6.82     |
| Feng et al         | 1.02 (0.35–2.94)  | 18.66    |
| Heikkila et al     | 2.18 (0.22–21.79) | 3.12     |
| Wang et al         | 1.47 (0.44–5.93)  | 12.06    |
| Zhou et al         | 1.20 (0.56–2.58)  | 33.39    |
| Li and Pu          | 1.56 (0.15–16.46)| 3.32     |
| Li and Zhang       | 1.76 (0.53–5.86)  | 11.30    |
| Feng and Wang      | 2.40 (0.65–8.90)  | 7.91     |
| Overall (I²=0.0%, P=0.806) | 1.71 (1.14–2.57) | 100      |

#### B

| Study ID           | OR (95% CI)       | % weight |
|--------------------|-------------------|----------|
| Tisel et al        | 4.44 (0.68–28.86) | 4.23     |
| Lee et al          | 4.52 (0.17–121.33)| 0.83     |
| Ito et al          | 2.95 (0.86–10.16) | 9.21     |
| Heikkila et al     | 0.61 (0.15–2.49)  | 20.85    |
| Miyauchi et al     | 1.91 (1.09–3.37)  | 64.88    |
| Overall (I²=2.0%, P=0.395) | 1.86 (1.17–2.96) | 100      |

#### C

| Study ID           | OR (95% CI)       | % weight |
|--------------------|-------------------|----------|
| Lim et al          | 0.92 (0.34–2.49)  | 10.08    |
| Lee et al          | 1.19 (0.05–26.97) | 2.68     |
| Jin et al          | 11.13 (1.34–92.60)| 4.79     |
| Feng et al         | 3.80 (1.24–11.64)| 9.31     |
| Heikkila et al     | 17.67 (0.84–372.35)| 2.78   |
| Main et al         | 3.37 (0.97–11.67)| 8.59     |
| Yao et al          | 2.19 (0.48–9.96)  | 7.12     |
| Shi et al          | 0.32 (0.04–2.86)  | 4.56     |
| Wang et al         | 7.29 (1.39–38.15)| 6.49     |
| Xu et al           | 3.14 (0.59–16.62)| 6.45     |
| Zhou et al         | 3.94 (1.59–9.75)  | 10.66    |
| Ito et al          | 1.96 (0.53–7.28)  | 8.19     |
| Li and Zhang       | 5.34 (0.26–108.26)| 2.84    |
| Li and Pu          | 7.31 (1.76–30.42)| 7.58     |
| Feng and Wang      | 0.24 (0.06–0.95)  | 7.87     |
| Overall (I²=50.2%, P=0.014) | 2.49 (1.42–4.39) | 100  |

#### D

| Study ID           | OR (95% CI)       | % weight |
|--------------------|-------------------|----------|
| Ito et al          | 11.77 (2.11–65.67)| 14.93    |
| Heikkila et al     | 0.46 (0.05–4.58)  | 11.28    |
| Main et al         | 60.79 (3.18–1,160.80)| 8.33 |
| Zong et al         | 21.00 (5.24–84.22)| 17.39    |
| Miyauchi et al     | 2.03 (0.59–6.91)  | 18.67    |
| Manuta et al       | 18.47 (2.18–156.63)| 12.21    |
| Ito et al          | 5.74 (1.39–23.63)| 17.19    |
| Overall (I²=59.8%, P=0.021) | 6.96 (2.46–19.69) | 100  |
no significant relationship was observed between PTC and mortality (HR =1.47, 95% CI: 2.23–5.18; Table S2).

Publication bias

The Begg’s test and funnel plot showed that there was no evidence of publication bias present among all the analyses in our meta-analysis (all \( P > 0.05 \); Figures 9 and 10).

Discussion

Cell proliferative activity is regarded as an important factor for evaluating the biologic behavior of cancer cells. It is a key process in the development of tumors when the balance between cell death and proliferation is destroyed. We used IHC to detect cell cycle-specific antigens and this method can assess the proliferative activity of cells. Ki-67/MIB-1 is the most widely used marker for assessing the proliferative capacity of tumor cells. Increased expression of Ki-67/MIB-1 has been linked to increased invasiveness in many cancers.\(^\text{10,65–67}\) Many meta-analyses have shown that high expression of Ki-67/MIB-1 contributed to poor survival in many tumors.\(^\text{68–72}\) However, there is no consensus on the association between high level of Ki-67/MIB-1 and thyroid cancer at present. Meta-analysis is a systematical method applied widely to evaluate the prognostic indicators in different trials. Thus, in this meta-analysis, we explored the diagnosis and prognosis of Ki-67/MIB-1 expression in thyroid cancer.

In our study, we found the valuable predicting effect of Ki-67/MIB-1 for the diagnosis of thyroid cancer with a high accuracy for Chinese. In clinical practice, detecting Ki-67/MIB-1 expression may contribute to diagnosing thyroid cancer when combined with clinical symptoms, laboratory examinations and other radiologic imaging. Our analysis demonstrated that patients with overexpression of Ki-67/MIB-1 seemed to have a poor survival in thyroid cancer. Also, Ki-67/MIB-1 was found to be associated with tumor size, lymph node metastasis, metastasis status, extrathyroid extension and other clinicopathologic parameters. However, the mechanism of Ki-67/MIB-1 in thyroid cancer is still unclear. Ki-67/MIB-1 as a cellular marker has a positive effect on cell proliferation. Ki-67/MIB-1 expression detected by IHC can evaluate tumor cell proliferation. A previous study confirmed that Sp1 plays an important role in regulation of Ki-67/MIB-1 gene expression.\(^\text{73}\) Another study pointed out that E2F2 transcription factor was positively correlated with Ki-67/MIB-1 expression in human glioblastoma\(^\text{74}\) and E2F1–3 factors are the transcriptional activator in tumor progression and the retinoblastoma tumor suppressor...
Ki-67/MIB-1 expression in thyroid cancer

which contributed to the heterogeneity. Also, various cut-off values were used to define thyroid cancer with Ki-67/MIB-1 positive expression by different investigators, which potentially contributed to the heterogeneity. So, it is difficult to apply a standard critical value in clinical practice. Spyratos et al\textsuperscript{76} found that few tumors with low proliferation rate were under misclassification when the cut-off value of Ki-67/MIB-1 was 10\%, and it is acceptable to identify a highly proliferative tumor with a Ki-67/MIB-1 cut-off value of 25\%. In this meta-analysis, the cut-off values of Ki-67/MIB-1 ranged from 0.5\% to 15.33\%.

Figure 7 Meta-analysis evaluating the association between Ki-67/MIB-1 and DFS (fixed-effect analysis).

Note: The combined fixed-effect HR was 5.19 (95% CI: 3.18–8.46, \(P=0.001\)), indicating that high level of Ki-67/MIB-1 was associated with worse DFS.

Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio.

pathway regulates E2F1–3 factors which could control cellular proliferation.\textsuperscript{75}

In this meta-analysis, heterogeneity existed among the studies. Heterogeneity was still a potential problem which affected the meta-analysis results, though random-effect models were used to analyze the data. Meanwhile, in order to reduce heterogeneity, only the studies with the method of IHC to detect Ki-67/MIB-1 were included in this meta-analysis. However, evaluation standards, study location, number of patients, sex and age of patients were different, which contributed to the heterogeneity. Also, various cut-off values were used to define thyroid cancer with Ki-67/MIB-1 positive expression by different investigators, which potentially contributed to the heterogeneity. So, it is difficult to apply a standard critical value in clinical practice. Spyratos et al\textsuperscript{76} found that few tumors with low proliferation rate were under misclassification when the cut-off value of Ki-67/MIB-1 was 10\%, and it is acceptable to identify a highly proliferative tumor with a Ki-67/MIB-1 cut-off value of 25\%. In this meta-analysis, the cut-off values of Ki-67/MIB-1 ranged from 0.5\%

Figure 8 Meta-analysis evaluating the association between Ki-67/MIB-1 and mortality (random-effect analysis).

Notes: The pooled fixed-effect HR was 3.56 (95% CI: 1.17–10.83, \(P=0.025\)), indicating that high level of Ki-67/MIB-1 was associated with increased of risk of mortality. Weights are from random-effect analysis.

Abbreviations: CI, confidence interval; HR, hazard ratio.
to 25%. Therefore, different Ki-67/MIB-1 cut-offs may cause heterogeneity. Higher sensitivity, specificity and DOR were found in patients with cut-off value >10% by diagnostic subgroup analysis. Furthermore, those patients may have worse mortality. Given the small size of studies included in mortality analysis, further research with larger sample size would be needed to explore the impact of Ki-67/MIB-1 on mortality. Besides, HRs were extracted from survival curves.

Figure 9 Assessment of publication bias for clinicopathologic parameters.
Notes: (A) Age; (B) tumor size; (C) lymph node metastasis; (D) metastasis status; (E) TNM stage; (F) extrathyroid extension.
Abbreviations: OR, odds ratio; SE, standard error; TNM, tumor node metastasis.
or calculated from data which might be less than another variance. Most of the studies included in diagnosis were from China; however, most of the studies related to DFS and mortality were from outside of China. We found that Ki-67/MIB-1 had a diagnostic value in Chinese. However, we did not have enough data to calculate the relationship between Ki-67/MIB-1 and mortality for Chinese. So, regional variation may become a score of heterogeneity. Besides, due to several types of thyroid cancer dealt with in the same study, we conducted subgroup analysis in this meta-analysis. Ki-67/MIB-1 had diagnostic effect on different thyroid cancer types. We did not find significant association between Ki-67/MIB-1 and different thyroid cancer types.

Despite the above limitations, the current meta-analysis proves the associations between high Ki-67/MIB-1 and tumor deterioration, poor DFS and increased mortality in patients with thyroid cancer. In conclusion, we showed that high expression of Ki-67/MIB-1 was significantly connected with tumor size, lymph metastasis, metastasis status, extrathyroid extension and poor prognosis of thyroid cancer in this study.

Conclusion

Our meta-analysis shows that Ki-67/MIB-1 may be a biomarker for clinical deterioration in Chinese and has an effect on prognosis in thyroid cancer among non-Chinese. Therefore, detection of Ki-67/MIB-1 in the clinic will be beneficial to the treatment and prognostic assessment for thyroid cancer patients. However, well-designed prospective studies are necessary to further confirm our results.

Acknowledgments

The study was supported by funds from the Guangxi Scientific Research and Technology Development Plan (1598011-4). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the paper.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedenius J. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid. 2003;13(4):371–380.
2. Sofiadis A, Tani E, Foukakis T, et al. Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol. 2009;35(2):369–374.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
4. Torre LA, Sauer AM, Chen MS, Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin. 2016;66(3):182–202.
5. Ito Y, Miyauchi A, Ito M, et al. Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy. Endocr J. 2014;61(8):821–824.
6. Ito Y, Tomoda C, Uruno T, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg. 2005;29(7):917–920.
27. Song Q, Wang D, Lou Y, et al. Diagnostic significance of CK19, TG, Ki67 and galecin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011;6:126.

28. Zhang Y, Meng Z, Zhang M, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis. Life Sci. 2014;118(1):39–45.

29. Horii A, Yoshida J, Sakai M, et al. Ki-67 positive fractions in benign and malignant thyroid tumours: application of flow cytometry. Acta Otolaryngol. 1999;119(5):617–620.

30. Chou SJ, Chen CM, Harn HJ, Chen CJ, Liu YC. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma. J Surg Res. 2001;99(1):75–83.

31. Tan A, Ett D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol. 2011;15(2):108–116.

32. Jovanovic R, Kostadinova-Kunovska S, Janesvka V, et al. Novel RET mutations in macdonian patients with medullary thyroid carcinoma: genotype-phenotype correlations. Pril (Makedon Akad Nauk Umet Odd Med Nauk). 2015;36(1):93–107.

33. Wang W, Johansson H, Bergholm U, Wilander E, Grimmelius L. Apoptosis and expression of the proto-oncogenes bcl-2 and p53 and the proliferation factor Ki-67 in human medullary thyroid carcinoma. Endocr Pathol. 1996;7(1):37–45.

34. Huang X, Zhang P, Chen J, Gao I, Ling Y. Expression of p21ras protein, tereanforming growth factor b1 and Ki-67 in papillary thyroid carcinoma. J Fujian Med University. 2000;2:129–131.

35. Nie M, Du M, Li X. Expression of cytokeratin19 and Ki67 in papillary thyroid carcinoma. Heilongiang Med J. 2005;29(3):168–169.

36. Liang F, Fu Q, Dai C, Wang G, Li J, Zhao M. Pathological study of papillary thyroid carcinoma and papillary thyroid hyperplasia. Cancer Res Clin. 2006;18(11):755–756.

37. Gan X, Zhu W, Zhang X, Wan L. The expression and significance of Ki-67 and CK-19 in papillary thyroid carcinoma. Zhejiang Practical Med. 2007;12(6):391–392.

38. Wang C, Sun J, Teng M, Huan D. Expression of RET, HBME-1 and Ki67 in thyroid benign and malignant tumors. Practical Oncol J. 2007;21(5):427–429.

39. Shang L, Yang Y, Li D, Wei D, Chen X. Expressions of CD26, Ki67 and EGFR proteins in primary thyroid neoplasms and their value in differential diagnosis. Chinese J Endocrinol Meta. 2008;24(2):174–177.

40. Feng W, Cao Y, Zhang J. Expression of Ki-67 and survivin in thyroid cancer and their significance. J Practical Med. 2009;25(19):3215–3218.

41. Wang L, Xi F, Yang Y, et al. Expression of survivin and Ki-67 and their significance in thyroid tumors. Shandong Med J. 2009;49(28):9–11.

42. Huang H, Mei J, Xu L, Chen R. Expression of CK19, Ki67 and VEGF and their clinical significances in papillary thyroid carcinoma. J Nan chang University (Medical Sciences). 2010;50(11):24–27.

43. Li N, Du J. Expression of HBME-1, CK19, Gal-3 and Ki-67 in papillary thyroid lesions. J Harbin Med University. 2010;44(6):575–578.

44. Hao G. The expression p53, p21 and Ki-67 in papillary thyroid carcinoma. China Modern Med. 2010;2(10):38–38.

45. Zeng X, Yang X, Wang T. Expression and significance of tumor-related factors COX-2 and Ki-67 in thyroid neoplasm tissue. Practical Preventive Med. 2011;18(4):612–614.

46. Qin L, Niu J, Liu S, He J, Xu Y. Significance and Expression of MCM3 and Ki-67 in Normal Thyroid, Nodular Goiter and Carcinoma. Journal of Shihezi University (Natural Science). 2012;30(3):356–360.

47. Zhao L, Lin J, Shi B, Lin Q, Huai Y, Wang K. Expression and clinical pathology significance of P53, ki-67, galecin-3, HBME-1, 34BE12 and CK19 in papillary thyroid carcinomas. Basic Amp Clin Med. 2012;32(10):1202–1206.

48. Jiang W, Wang Y, Chen M, Zhu C. Expression and relationship of XIAP, P53 and Ki67 in papillary thyroid carcinoma. BMBJ. 2012;34(11):971–974.
49. Yao H, Wei Z, Liang X, et al. The expressin and prognosis of tumor metastasis gene KISS-1 in the tissues of thyroid cancer. *Chinese Remedies Clinics*. 2012;12(11):1408–1411.

50. Yang R, Teng X, Ding W, Sun K. Expressions of MCM2, Ki67, CyclinD1 in Follicular Carcinoma and Follicular Adenoma of the Thyroid and the Comparison with Galectin-3 and CK19. *J Basic Clin Oncol*. 2013;(6):464–468.

51. Li X. Expression and clinical significance of Receptor for Activated Protein C Kinase 1 and Ki67 in papillary thyroid carcinoma. *J Dalian Med University*. 2013.

52. Shi L, Zhang A, Luo Y, Zhao S, Tian H, Yang Y. Abnormal expressions of positive cell cycle control factors and thyroid carcinoma occurrence and progression. *J Southern Med University*. 2013;33(7):1031–1035.

53. Guo M, Xing Y, Chen W, Zhang J, Meng D. Bcl-1, P53 and Ki-67 expression in the thyroid carcinoma and its clinical significance. *J Modern Oncol*. 2014;22(6):1294–1297.

54. Wang Y, Wang H, Zhu H. Expression and diagnostic value of CK19, HBME-1 and MIB-1 in between hyalinizing trabecular tumor and thyroid papillary carcinoma. *Practical Oncol J*. 2014;(4):326–330.

55. Zhou Y, Jiang H, Lu B, Chen Z, Lu N, Li J. Expression and Clinical Significance of Ki67, CK19, Galectin-3 and HBME-1 in Papillary Thyroid Carcinoma Zhejiang. *Practical Med*. 2014;19(6):395–397.

56. Li T, Wu G, Cai D. Clinical significance of four immunohistochemical markers in the diagnosis of the papillary thyroid carcinoma. *Shanghai Med Pharm J*. 2014;35(10):24–27.

57. Xu Y, Li X, Yu J. The relationship between BRAF gene mutation and Ki67 protein expression in papillary thyroid carcinoma. *J Nanchang University (Medical Sciences)*. 2014;54(10):12–14.

58. Wang L, Sun J, Hou H, Peng J. The expression and significance of Ki-67 in thyroid papillary carcinomas. *J Chinese Physician*. 2014;16(1):76–78.

59. Zhu C, Shuai J, Shao Q, Hu G. Discuss application of antibody marker MC combining with CK19, CK19, TPO, Galectin-3, Ki-67 in thyroid papillary lesions. *World Latest Med Info*. 2015;(53):11–12.

60. Li G, Pu Y. Expression of CD147 and Ki-67 in papillary thyroid cancer and significance. *J Modern Oncol*. 2015;23(13):1818–1820.

61. Li Y, Zhang J. Clinical Significance of the ProteintExpression of MCM7, CDK2 and Ki-67 in Thyroid Cancer. *Practical J Cancer*. 2015;9(3):359–361.

62. Feng J, Wang J. Expression and clinical significance of Ki67 and calcitonin in medullary thyroid carcinoma. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2014;28(24):1921–1924. Chinese.

63. Cui W, Chen X, Liu C, Zhang W. Expressions of Gal-3, PTTG and Ki-67 in primary thyroid neoplasms and their value in differential diagnosis. *Shanxi Medical J*. 2009;38(6):670–672.
**Supplementary materials**

**Table S1** Subgroup analysis evaluating the diagnostic value of Ki-67/MiB-1 in thyroid cancer

| Groups | No of studies | Pooled sensitivity (95% CI) | Pooled specificity (95% CI) | DOR (95% CI) |
|--------|---------------|-----------------------------|-----------------------------|--------------|
| Cut-off, % |               |                             |                             |              |
| ≤5     | 12            | 0.70 (0.67–0.73)            | 0.80 (0.77–0.83)            | 7.49 (3.61–15.52) |
| 10     | 15            | 0.56 (0.53–0.59)            | 0.67 (0.63–0.70)            | 7.73 (2.68–22.30) |
| >10    | 8             | 0.78 (0.75–0.81)            | 0.79 (0.74–0.84)            | 15.40 (3.41–69.62) |
| Types  |               |                             |                             |              |
| PTC    | 21            | 0.63 (0.60–0.65)            | 0.74 (0.72–0.76)            | 8.22 (4.08–16.56) |
| PTMC   | 2             | 0.45 (0.37–0.52)            | 0.86 (0.77–0.92)            | 4.76 (2.48–9.17)  |

**Abbreviations:** CI, confidence interval; DOR, diagnostic odds ratio; PTC, papillary thyroid carcinoma; PTMC, papillary thyroid microcarcinoma.

**Table S2** Subgroup analysis evaluating the prognostic value of Ki-67/MiB-1 for mortality in thyroid cancer

| Groups | Pooled HR | 95% CI | Heterogeneity test | Statistical method |
|--------|-----------|--------|--------------------|--------------------|
|        |           |        | I², % | P-value |                   |
| Univariate cut-off, % |           |        |        |         |                   |
| ≤5     | 1.98      | 0.65–6.06 | 68.80 | 0.007   | Random            |
| >5     | 28.06     | 6.68–117.87 | 0.00  | 0.818   | Random            |
| <10    | 2.73      | 0.89–8.38  | 72.20 | 0.001   | Random            |
| Types  |           |         |       |         |                   |
| PTC    | 1.47      | 2.23–5.18  | 87.10 | <0.001  | Random            |
| MTC    | 0.96      | 0.24–2.16  | 65.50 | 0.035   | Random            |

**Abbreviations:** CI, confidence interval; HR, hazard ratio; MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma.